Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Signs Japan Marketing Deal with Eidia

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Under the deal, Eidia, which is the diagnostics subsidiary of Eisai, will have access to Seegene's TOCE (tagging oligonucleotide capture and extension) multiplex molecular diagnostic tests. The Japanese firm will exclusively market and distribute the tests in Japan, and it will seek regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.

"Our partnership with Eidia opens a significant sales channel for our novel diagnostic tests in Japan," Jong-Yoon Chun, founder, CTO, and CEO of Seegene, said in a statement. "We look forward to working with Eidia to improve patient healthcare with highly sensitive and specific multiplexed MoDx tests."

Further terms of the agreement were not disclosed.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.